ArticleJournal of gynecologic oncology2024
The new 2023 FIGO staging system for endometrial cancer: what is different from the previous 2009 FIGO staging system?
Article in Journal of gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer.Journal of clinical medicine · 2026Article
- Risk-Based Survival Outcomes in Early-Stage Endometrial Cancer: Impact of Radiation Therapy.Journal of Korean medical science · 2026Article
- Prognostic Value of p53 Status in Endometrial Cancer: Real-World Evidence from a Tertiary Center.Cancers · 2026Article
- Clinical outcomes and adjuvant therapy in stage IC endometrial cancer under the revised 2023 FIGO staging system: a multicenter analysis.Journal of gynecologic oncology · 2026Article
- Survival and Safety Outcomes of Three-Cycle Adjuvant Chemotherapy in Intermediate-Risk Endometrial Cancer.Cancers · 2026Article
- Impact of the 2023 FIGO staging system on risk stratification in endometrial cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Prognostic Impact of POLE Exonuclease-Domain Mutations in Endometrial Cancer: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Hormone receptor status score is negatively correlated with adverse pathological features and serves as an independent prognostic factor in endometrial carcinoma.American journal of translational research · 2026Article
- The past, present, and future of FIGO staging of endometrial cancer.Journal of gynecologic oncology · 2025Review
- Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Impact of the FIGO 2023 Staging System on the Adjuvant Treatment of Endometrial Cancer: A Comparative Analysis with FIGO 2009.Cancers · 2025Article
- Article
- Artificial intelligence-based spatial analysis of tertiary lymphoid structures and clinical significance for endometrial cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers.Journal of gynecologic oncology · 2025Review
- External Validation of the New 2023 International Federation of Gynecology and Obstetrics Staging System in Endometrial Cancer Patients: 12-Year Experience from an European Society of Gynecological Oncology-Accredited Center.Medicina (Kaunas, Lithuania) · 2024Article
- Clinical application of FIGO 2023 staging system of endometrial cancer in a Chinese cohort.BMC cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe International Federation of Gynecology and Obstetrics committee modified the endometrial cancer (EC) staging system based on the histopathological feature and molecular profile. The aim is to evaluate the clinical implications of the new 2023 system compared with the previous 2009 system.
methodsWe retrospectively identified 161 patients with EC who underwent primary surgical treatment between 2014 and 2018 at Seoul National University Hospital. The droplet-digital polymerase chain reaction for
resultsThe median follow-up period was 62.9 months (range, 0.3-110.9), and the median age was 57.2 years old (range, 28.0-85.9). The 5-year progression-free survival (PFS) for the 2023 system with molecular classification was 80.3% for stage I, 75.2% for stage II, 61.2% for stage III, and 22.2% for stage IV (p<0.001). Patients with the 2009 stage I and II disease were restaged using the 2023 system. In contrast, patients with stage III and IV disease were fixed in the 2009 and 2023 systems. Molecular classification downstaged 10 patients (71.4%) to IAm
conclusionThe 2023 staging system for EC subdivided stages I and II compared to the 2009 system. The 2023 system with molecular classification is a good predictor of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.